Jagsonpal Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Jagsonpal Pharmaceuticals için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.8%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Oct 14

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Jagsonpal Pharmaceuticals yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:JAGSNPHARM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2024	2,269	243	573	575	N/A
6/30/2024	2,100	203	N/A	N/A	N/A
3/31/2024	2,087	225	349	352	N/A
12/31/2023	2,207	245	N/A	N/A	N/A
9/30/2023	2,336	283	492	498	N/A
6/30/2023	2,363	313	N/A	N/A	N/A
3/31/2023	2,367	267	463	467	N/A
12/31/2022	2,410	223	N/A	N/A	N/A
9/30/2022	2,348	198	-2	-1	N/A
6/30/2022	2,326	131	N/A	N/A	N/A
3/31/2022	2,176	189	59	69	N/A
12/31/2021	2,168	247	N/A	N/A	N/A
9/30/2021	2,194	247	308	316	N/A
6/30/2021	2,163	214	N/A	N/A	N/A
3/31/2021	1,879	171	278	282	N/A
12/31/2020	1,746	135	N/A	N/A	N/A
9/30/2020	1,595	104	200	210	N/A
6/30/2020	1,450	84	N/A	N/A	N/A
3/31/2020	1,586	79	100	119	N/A
12/31/2019	1,675	93	N/A	N/A	N/A
9/30/2019	1,673	88	N/A	N/A	N/A
6/30/2019	1,697	85	N/A	N/A	N/A
3/31/2019	1,668	72	286	309	N/A
12/31/2018	1,611	30	N/A	N/A	N/A
9/30/2018	1,573	-10	N/A	N/A	N/A
6/30/2018	1,421	-66	N/A	N/A	N/A
3/31/2018	1,266	-116	N/A	-16	N/A
12/31/2017	1,234	-95	N/A	N/A	N/A
9/30/2017	1,193	26	N/A	N/A	N/A
6/30/2017	1,305	70	N/A	N/A	N/A
4/1/2017	1,441	119	N/A	-32	N/A
12/31/2016	1,534	131	N/A	N/A	N/A
9/30/2016	1,537	35	N/A	N/A	N/A
6/30/2016	1,466	34	N/A	N/A	N/A
3/31/2016	1,435	33	N/A	90	N/A
12/31/2015	1,434	13	N/A	N/A	N/A
9/30/2015	1,412	10	N/A	N/A	N/A
6/30/2015	1,412	9	N/A	N/A	N/A
3/31/2015	1,382	12	N/A	43	N/A
12/31/2014	1,306	23	N/A	N/A	N/A
9/30/2014	1,359	32	N/A	N/A	N/A
6/30/2014	1,397	28	N/A	N/A	N/A
3/31/2014	1,439	21	N/A	75	N/A
12/31/2013	1,507	12	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: JAGSNPHARM 'un tahmini kazanç büyümesinin tasarruf oranının ( 6.7% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: JAGSNPHARM 'un kazançlarının Indian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: JAGSNPHARM şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: JAGSNPHARM şirketinin gelirinin Indian pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: JAGSNPHARM şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: JAGSNPHARM 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Jagsonpal Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Jagsonpal Pharmaceuticals Limited Announces Resignation of Ashish Lakhotia as Chief Financial Officer

Jagsonpal Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 23, 2024

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹5.00 per share

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2024

First quarter 2025 earnings released: EPS: ₹1.94 (vs ₹2.85 in 1Q 2024)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 07, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Market cap size

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

Full year 2024 earnings released: EPS: ₹8.49 (vs ₹10.20 in FY 2023)

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Investor sentiment improves as stock rises 16%

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Now 20% undervalued after recent price drop

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: ₹1.48 (vs ₹2.97 in 3Q 2023)

Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes

Jagsonpal Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 01, 2024

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: ₹2.84 (vs ₹3.97 in 2Q 2023)

Jagsonpal Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 03, 2023

Upcoming dividend of ₹5.00 per share at 1.1% yield

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Aug 31, 2023

First quarter 2024 earnings released: EPS: ₹2.85 (vs ₹0.14 in 1Q 2023)

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings released: EPS: ₹10.20 (vs ₹7.48 in FY 2022)

Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Investor sentiment improves as stock rises 15%

Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer

Third quarter 2023 earnings released: EPS: ₹2.97 (vs ₹2.06 in 3Q 2022)

Jagsonpal Pharmaceuticals Limited Announces Executive Changes

Investor sentiment improved over the past week

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹3.97 (vs ₹2.79 in 2Q 2022)

High number of new and inexperienced directors

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 14, 2022

First quarter 2023 earnings released: EPS: ₹0.14 (vs ₹2.61 in 1Q 2022)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: ₹748 (vs ₹6.51 in FY 2021)

Jagsonpal Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment improved over the past week

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Jagsonpal Pharmaceuticals Limited Announces Resignation of Sanjiv Kumar Dudeja as Chief Financial Officer

Investor sentiment improved over the past week

Upcoming dividend of ₹4.00 per share

Second quarter 2022 earnings released: EPS ₹2.79 (vs ₹1.53 in 2Q 2021)

Upcoming dividend of ₹1.00 per share

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹2.61 (vs ₹0.96 in 1Q 2021)

Investor sentiment improved over the past week

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Full year 2021 earnings released: EPS ₹6.51 (vs ₹3.00 in FY 2020)

Investor sentiment improved over the past week

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

New 90-day high: ₹93.35

Investor sentiment improved over the past week

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Jagsonpal Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 12, 2021

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio